BridgeMD
Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease - Randomized Delayed-Start Pilot Trial
EU CTIS ID: 2024-514543-28-00
What this study is testing
Évaluer l’impact de la vaccination antigrippale à 1 mois sur la réponse inflammatoire systémique (hsCRP) chez les patients atteints d’une maladie coronarienne stable.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Subjects aged ≥ 60 years.
- - With documented stable coronary artery disease.
- - Subjects who, in the opinion of the investigator, can comply with protocol requirements (i.e., show up for the follow-up visit and be able to converse with study staff).
- - Signature of free, written and informed consent by the patient.
- - Subjects aged ≥ 60 years. - With documented stable coronary artery disease. - Subjects who, in the opinion of the investigator, can comply with protocol requirements (i.e., show up for the follow-up visit and be able to converse with study staff). - Signature of free, written and informed consent by the patient. - Affiliation to a French social security system.
You likely can't join if
- - History of serious reaction to influenza vaccine or refusal of vaccination or contraindication to vaccination.
- - Participant has received the influenza vaccine within <6 months or another vaccine.
- - Acute infection within <3 months or acute worsening of chronic diseases.
- - Severe neurocognitive disorders (inability to give informed consent).
- - Pre-existing medical conditions or medications involving the immune system (rheumatoid arthritis or other inflammatory conditions or active cancer, recent use (within the past year) of immunosuppressive or modulating agents, including oral steroids, chemotherapy, or radiation therapy) .
- - Cardiovascular surgery or other interventions within 6 months preceding the study or planned during the follow-up period.
See the full eligibility criteria
- - Subjects aged ≥ 60 years.
- - With documented stable coronary artery disease.
- - Subjects who, in the opinion of the investigator, can comply with protocol requirements (i.e., show up for the follow-up visit and be able to converse with study staff).
- - Signature of free, written and informed consent by the patient.
- - Subjects aged ≥ 60 years. - With documented stable coronary artery disease. - Subjects who, in the opinion of the investigator, can comply with protocol requirements (i.e., show up for the follow-up visit and be able to converse with study staff). - Signature of free, written and informed consent by the patient. - Affiliation to a French social security system.
- - History of serious reaction to influenza vaccine or refusal of vaccination or contraindication to vaccination.
- - Participant has received the influenza vaccine within <6 months or another vaccine.
- - Acute infection within <3 months or acute worsening of chronic diseases.
- - Severe neurocognitive disorders (inability to give informed consent).
- - Pre-existing medical conditions or medications involving the immune system (rheumatoid arthritis or other inflammatory conditions or active cancer, recent use (within the past year) of immunosuppressive or modulating agents, including oral steroids, chemotherapy, or radiation therapy) .
- - Cardiovascular surgery or other interventions within 6 months preceding the study or planned during the follow-up period.
- - Patient's wish or clinical situation requiring co-administration with other vaccines or any factor hindering monitoring.
- - Patient under guardianship, curatorship or safeguard of justice.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.